" if patients receive chemical ovarian ablation (ovary shutdown) and truly have suppression of estrogen production, that aromatase inhibitors can be very effective. In premenopausal women who have early stage breast cancer, this is a research question. "
In other words, there seems to be no data on chemical ovarian ablation WITHOUT tamoxifen, or with an AI on top of the chemically-induced menopause as of 2008. Why?
In the metastatic setting, ovarian ablation and tamoxifen monotherapies produce comparable outcomes and MAY be more effective when used together.
Now, this is not early-stage breast cancer, obviously.
[There is] significantly greater disease-free and overall survival rates for women under the age of 50, regardless of nodal status, receiving ovarian ablation as a single adjuvant therapy.
Ovarian ablation followed by some years of tamoxifen produces similar results to those seen with adjuvant chemotherapy in women with hormone-receptor positive breast cancer; however, the value of combining these modalities is still unclear.
Unsaid is what ovarian ablation without tamoxifen.
Other areas of ongoing investigation include the appropriate duration of therapy with LHRH analogues in the adjuvant setting, the long-term sequelae of ovarian suppression among young breast cancer survivors, and refinement of the population most likely to benefit from ovarian ablation or suppression.
Here's some other info.:
Potentially reversible castration can be accomplished medically using luteinizing hormone releasing hormone (LHRH) analogues.
So that's what is next here.